Physician profile
Patrick S Fluck
NPI 1659341394
$2,272.54
in general payments reported to CMS, 2019-2025
33 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $95.95 · 2021: $12.17 · 2022: $260 · 2023: $490 · 2024: $625 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510 · Education: $87.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.04 |
| Education | $87.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $415.76 | 2022-2025 | Acthar |
| Travere Therapeutics, INC. | $222.09 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $176.92 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $162.69 | 2019-2025 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $154.58 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $96.97 | 2019-2025 | Jynarque |
| Amgen INC. | $90.11 | 2019-2025 | Tavneos, Krystexxa |
| Ani Pharmaceuticals, INC. | $88.60 | 2023-2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $84.71 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $83.30 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $68.52 | 2019-2022 | |
| Novo Nordisk INC | $59.23 | 2024-2025 | Ozempic, Rybelsus |
| Mallinckrodt Enterprises LLC | $48.34 | 2019 | |
| Medtronic, INC. | $47.94 | 2021-2022 | |
| Kyowa Kirin, INC. | $46.27 | 2024 | Crysvita |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $42.31 | 2019 | |
| Pharmacosmos Therapeutics INC. | $40.60 | 2024-2025 | Monoferric |
| Chiesi USA, INC. | $36.54 | 2022-2025 | Elfabrio |
| Alexion Pharmaceuticals, INC. | $33.80 | 2019-2024 | Ultomiris |
| Fresenius USA Marketing, INC. | $31.79 | 2025 | Velphoro |
| Genzyme Corporation | $30.78 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $29.28 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.67 | 2023 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.25 | 2023 | Jardiance |
| Aurinia Pharma U.S., INC. | $18.77 | 2023 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $18.38 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $17.62 | 2022 | |
| Neurocrine Biosciences, INC. | $16.21 | 2024 | |
| Medtronic Minimed, INC. | $16.03 | 2020 | |
| Lilly USA, LLC | $15.29 | 2024 | Mounjaro, Zepbound |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Fluck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.